Neurocrine Biosciences Inc

Market Summary

USD117.28-2.72

Market Closed

-2.27%

NBIX Alerts

3 major insider sales recently.
Big jump in Revenue (Y/Y)

NBIX Stock Price

View Fullscreen

NBIX RSI Chart

NBIX Alerts

3 major insider sales recently.
Big jump in Revenue (Y/Y)

NBIX Valuation

Market Cap

11.5B

Price/Earnings (Trailing)

60.3

Price/Sales (Trailing)

6.46

EV/EBITDA

41.08

Price/Free Cashflow

29.94

NBIX Price/Sales (Trailing)

NBIX Profitability

EBT Margin

14.12%

Return on Equity

9.54%

Return on Assets

6.71%

Free Cashflow Yield

3.34%

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

1.8B

Revenue Y/Y

28.59%

Revenue Q/Q

10.18%

NBIX Earnings

Earnings (TTM)

191.0M

Earnings Y/Y

21.31%

Earnings Q/Q

-12.98%

Price Action

Last 7 days

0.1%

Last 30 days

1.6%

Last 90 days

7.3%

Trailing 12 Months

-2.6%

How does NBIX drawdown profile look like?

NBIX Financial Health

Current Ratio

2.39

NBIX Investor Care

Shares Dilution (1Y)

2.51%

Diluted EPS (TTM)

1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.6B	1.7B	1.8B	0
2022	1.2B	1.3B	1.4B	1.5B
2021	1.0B	1.0B	1.1B	1.1B
2020	886.8M	1.0B	1.0B	1.0B
2019	518.6M	605.1M	675.5M	788.1M
2018	232.7M	323.3M	414.3M	451.2M
2017	51.7M	88.3M	125.0M	161.6M
2016	15.0M	15.0M	15.0M	15.0M
2015	0	0	0	19.8M
2014	0	0	0	0
2013	40.6M	28.0M	15.5M	2.9M
2012	76.2M	74.6M	42.3M	53.1M
2011	45.3M	52.8M	80.0M	77.4M
2010	10.6M	18.2M	25.9M	33.5M
2009	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for NBIX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 01, 2023	lyons gary a	acquired	64,900	12.98	5,000	-
Dec 01, 2023	lyons gary a	sold	-583,837	116	-5,000	-
Nov 29, 2023	onyia jude	sold	-264,733	113	-2,331	chief scientific officer
Nov 27, 2023	lippoldt darin	sold	-1,225,910	112	-10,919	chief legal officer
Nov 16, 2023	sherwin stephen a	gifted	-	-	-2,750	-
Oct 02, 2023	boyer david w.	sold	-161,921	112	-1,437	chief corp. affairs officer
Sep 12, 2023	lyons gary a	acquired	64,900	12.98	5,000	-
Sep 12, 2023	lyons gary a	sold	-575,120	115	-5,000	-
Sep 01, 2023	lyons gary a	sold	-550,316	110	-5,000	-
Sep 01, 2023	cooke julie	sold	-91,406	110	-824	chief human resources officer

Which funds bought or sold NBIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 07, 2023	Hudson Bay Capital Management LP	added	29.03	3,941,750	11,250,000	0.04%
Dec 06, 2023	CITIGROUP INC	reduced	-9.22	1,637,790	21,357,900	0.02%
Nov 27, 2023	TRUST CO OF VERMONT	sold off	-100	-9,996	-	-%
Nov 24, 2023	DEUTSCHE BANK AG\	reduced	-22.43	-2,514,960	31,196,300	0.02%
Nov 22, 2023	Aurora Investment Counsel	reduced	-0.92	231,896	1,505,700	1.00%
Nov 22, 2023	KBC Group NV	unchanged	-	-	2,811,000	0.01%
Nov 22, 2023	Polar Capital Holdings Plc	reduced	-13.33	1,200,000	36,562,500	0.27%
Nov 21, 2023	Walleye Capital LLC	new	-	3,455,210	3,455,210	0.01%
Nov 21, 2023	COMERICA BANK	new	-	7,418	7,418	-%
Nov 21, 2023	COMERICA BANK	added	756	17,431,700	17,491,700	0.09%

Latest Funds Activity

Are funds buying NBIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NBIX

No. of Funds

Schedule 13G FIlings of Neurocrine Biosciences Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	janus henderson group plc	2.5%	2,415,638	SC 13G/A
Feb 09, 2023	vanguard group inc	9.72%	9,340,295	SC 13G/A
Jan 23, 2023	blackrock inc.	13.1%	12,627,403	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	4.5%	4,359,645	SC 13G/A
Feb 10, 2022	vanguard group inc	9.26%	8,787,991	SC 13G/A
Feb 10, 2022	janus henderson group plc	7.8%	7,445,839	SC 13G/A
Jan 27, 2022	blackrock inc.	12.1%	11,476,545	SC 13G/A
Jan 26, 2022	blackrock inc.	12.1%	11,476,545	SC 13G/A
Aug 10, 2021	fmr llc	-	0	SC 13G/A
Apr 12, 2021	blackrock inc.	11.7%	10,989,646	SC 13G/A

Recent SEC filings of Neurocrine Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Dec 08, 2023	4	Insider Trading
Dec 08, 2023	4	Insider Trading
Dec 06, 2023	144	Notice of Insider Sale Intent
Dec 06, 2023	144	Notice of Insider Sale Intent
Dec 05, 2023	4	Insider Trading
Dec 01, 2023	144	Notice of Insider Sale Intent
Dec 01, 2023	4	Insider Trading
Nov 29, 2023	144	Notice of Insider Sale Intent
Nov 29, 2023	4	Insider Trading
Nov 27, 2023	144	Notice of Insider Sale Intent

NBIX Fair Value

Peers (Alternatives to Neurocrine Biosciences Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	389.5B	102.8B	2.69%	-12.25%	11.25	3.79	11.47%	80.74%
MRK	272.8B	59.3B	-0.63%	-5.14%	17.88	4.63	0.58%	-69.80%
PFE	162.5B	68.5B	-6.62%	-44.42%	15.5	2.37	-31.38%	-64.79%
AMGN	144.0B	26.8B	-1.52%	-4.93%	19.03	5.37	1.91%	10.69%
GILD	98.5B	27.4B	1.44%	-10.10%	16.77	3.6	0.94%	76.21%
MID-CAP
TEVA	11.0B	15.3B	7.32%	18.03%	-4.98	0.72	0.87%	-71.24%
ALKS	4.3B	1.6B	4.36%	1.49%	20.08	2.71	40.56%	266.27%
PRGO	4.0B	4.7B	2.10%	-7.72%	-978.12	0.86	5.74%	96.18%
AMPH	2.7B	601.3M	24.99%	94.42%	20.1	4.52	24.02%	75.17%
BHC	2.7B	8.5B	1.81%	-4.07%	-2.77	0.31	5.11%	-479.13%
SMALL-CAP
TLRY	1.4B	650.9M	10.34%	-28.86%	-0.96	2.13	6.08%	-185.21%
TXMD	22.1M	-	-5.00%	-65.05%	0.32	0.55	-19.54%	888.31%
ACOR	15.2M	111.1M	27.41%	2089.90%	-0.96	0.14	-10.43%	84.90%
ACRX	12.5M	-	39.62%	-61.05%	-0.59	0.13	287.27%	-145.15%
AGRX	5.2M	20.0M	16.16%	1110.53%	-0.38	0.26	137.71%	66.04%

Neurocrine Biosciences Inc News

Latest updates

Yahoo Finance • 09 Dec 2023 • 04:05 pm • 6 hours ago

Insider Sell: Chief Medical Officer Eiry Roberts Sells Shares of ...

MarketBeat • 07 Dec 2023 • 02:37 pm • 2 days ago

UniSuper Management Pty Ltd Makes New Investment in ...

BioSpace • 06 Dec 2023 • 08:55 am • 3 days ago

Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans ...

Marketscreener.com • 05 Dec 2023 • 09:02 pm • 4 days ago

Neurocrine Biosciences Receives Breakthrough Therapy ...

Investing.com Australia • 04 Dec 2023 • 09:29 pm • 5 days ago

Pro Research: Wall Street dives into Neurocrine Biosciences By ...

Investing.com Türkiye • 04 Dec 2023 • 09:25 pm • 5 days ago

Profesyonel Araştırma: Wall Street Neurocrine Biosciences'a dalıyor ...

Investing.com France • 04 Dec 2023 • 09:20 pm • 5 days ago

Recherche pro : Wall Street s'intéresse à Neurocrine Biosciences ...

Investing.com Italia • 04 Dec 2023 • 09:20 pm • 5 days ago

Ricerca professionale: Wall Street si immerge in Neurocrine ...

Yahoo Finance • 02 Dec 2023 • 10:06 am • 7 days ago

Insider Sell Alert: Chief Scientific Officer Jude Onyia Sells Shares of ...

Marketscreener.com • 01 Dec 2023 • 12:01 pm • 8 days ago

Neurocrine Biosciences to Host Analyst Day on December 5, 2023

Nasdaq • 30 Nov 2023 • 08:00 am • 9 days ago

Guru Fundamental Report for NBIX

Investing.com • 27 Nov 2023 • 03:26 pm • 12 days ago

Pro Research: Wall Street digs into Neurocrine Biosciences ...

GuruFocus.com • 14 Nov 2023 • 08:00 am • 25 days ago

Steven Cohen's Point72 Asset Management Adjusts Portfolio ...

MarketWatch • 10 Nov 2023 • 08:00 am • 29 days ago

Neurocrine Biosciences trial failures may 'stunt momentum,' analysts say

Morningstar • 10 Nov 2023 • 08:00 am • 29 days ago

Lions Gate shares rise on surprise profit, Plug Power stock plunges ...

Financials for Neurocrine Biosciences Inc

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	10.2%	499	453	420	412	388	378	311	312	296	289	237	248	259	302	237	244	222	184	138	131	152
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	-	1.00	2.00	2.00
Costs and Expenses	-5.7%	358	379	535	309	300	324	308	348	252	226	205	176	303	226	178	-	132	149	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	176	303	226	178	195	132	149	239	110	97.00
S&GA Expenses	-7.9%	204	222	243	183	186	183	201	157	155	143	129	107	113	97.00	118	101	85.00	81.00	88.00	69.00	60.00
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	73.00	-	-	-	58.00	-	-	62.00	38.00	39.00	35.00
EBITDA Margin	0.5%	0.15*	0.15*	0.07*	0.16*	0.08*	0.04*	0.11*	0.12*	0.18*	0.10*	0.13*	0.14*	0.14*	0.26*	0.26*	-	-	-	-	-	-
Interest Expenses	-15.4%	1.00	1.00	1.00	1.00	1.00	2.00	3.00	7.00	7.00	6.00	6.00	8.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Income Taxes	24.5%	33.00	26.00	-26.70	29.00	29.00	-6.40	8.00	-6.50	8.00	15.00	-4.90	-306	1.00	4.00	2.00	5.00	5.00	1.00	-0.50	-	-
Earnings Before Taxes	-4.9%	116	122	-103	118	98.00	-23.30	21.00	-13.80	31.00	58.00	27.00	42.00	-57.10	83.00	39.00	39.00	58.00	52.00	-102	19.00	51.00
EBT Margin	0.9%	0.14*	0.14*	0.06*	0.14*	0.06*	0.01*	0.08*	0.09*	0.15*	0.07*	0.09*	0.10*	0.10*	0.22*	0.21*	-	-	-	-	-	-
Net Income	-13.0%	83.00	96.00	-76.60	89.00	69.00	-16.90	14.00	-7.30	23.00	42.00	32.00	348	-57.60	80.00	37.00	34.00	54.00	51.00	-102	18.00	51.00
Net Income Margin	1.5%	0.11*	0.11*	0.04*	0.10*	0.04*	0.01*	0.06*	0.08*	0.42*	0.35*	0.38*	0.39*	0.09*	0.20*	0.20*	-	-	-	-	-	-
Free Cashflow	18.3%	204	173	-133	141	101	129	-48.10	-4.70	56.00	99.00	83.00	84.00	-17.90	117	34.00	-	-	-	-	-	-

Balance Sheet
(In Millions)

Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	9.0%	2,848	2,613	2,360	2,369	2,143	2,006	2,145	2,073	2,017	1,956	1,846	1,735	1,503	1,516	1,362	1,306	1,180	1,067	958	993	934
Current Assets	10.2%	1,650	1,497	1,433	1,454	1,206	1,019	1,018	973	1,006	1,110	1,085	1,016	1,157	1,146	968	831	819	749	633	738	714
Cash Equivalents	83.3%	294	160	104	263	212	163	270	344	311	368	353	190	425	415	187	116	172	147	78.00	147	201
Inventory	-9.1%	29.00	32.00	33.00	35.00	37.00	29.00	29.00	31.00	26.00	28.00	30.00	28.00	21.00	22.00	21.00	17.00	11.00	12.00	13.00	11.00	6.00
Net PPE	4.9%	69.00	66.00	63.00	59.00	61.00	67.00	64.00	59.00	51.00	50.00	45.00	45.00	43.00	45.00	42.00	42.00	40.00	40.00	37.00	34.00	29.00
Liabilities	11.3%	846	760	675	661	599	582	753	699	671	677	641	609	698	684	662	669	605	583	548	512	486
Current Liabilities	18.7%	692	583	374	538	485	286	254	246	226	213	190	187	611	573	140	565	116	101	72.00	88.00	456
Shareholder's Equity	8.0%	2,002	1,853	1,685	1,708	1,545	1,423	1,391	1,374	1,346	1,279	1,206	1,126	804	831	700	637	575	484	409	481	448
Retained Earnings	21.4%	-304	-387	-483	-406	-495	-564	-547	-635	-628	-651	-693	-725	-1,073	-1,015	-1,095	-1,132	-1,166	-1,220	-1,271	-1,177	-1,195
Additional Paid-In Capital	3.0%	2,309	2,242	2,171	2,122	2,054	2,000	1,948	2,011	1,974	1,929	1,898	1,850	1,874	1,842	1,797	1,768	1,740	1,703	1,681	1,660	1,645
Shares Outstanding	0.6%	98.00	98.00	98.00	97.00	96.00	96.00	95.00	95.00	95.00	95.00	94.00	94.00	93.00	93.00	93.00	92.00	92.00	91.00	91.00	91.00	91.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	18.0%	212,000	179,600	-125,200	143,000	98,800	138,100	-40,500	4,200	61,800	103,200	87,300	94,500	-20,400	118,900	35,500	97,500	97,800	64,200	-112,500	50,490	68,917
Share Based Compensation	-30.2%	47,800	68,500	39,900	43,500	43,100	49,500	37,000	35,600	37,100	28,600	32,900	21,000	26,700	29,500	22,800	21,300	20,300	17,900	15,800	13,300	13,070
Cashflow From Investing	22.7%	-97,300	-125,900	-42,100	-115,600	-61,300	31,400	-31,600	23,700	-126,200	-90,800	63,100	-147,700	25,200	93,400	33,200	-166,200	-85,600	-300	41,000	-106,241	-45,095
Cashflow From Financing	548.3%	18,800	2,900	8,200	24,600	11,400	-276,400	6,100	1,800	7,500	3,000	15,100	-185,000	5,400	15,800	6,000	12,400	13,100	4,300	2,600	1,752	5,490

NBIX Income Statement

2023-09-30

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Revenues	$ 498.8	$ 387.9	$ 1,371.9	$ 1,076.7
Operating expenses:
Cost of revenues	11.2	6.1	31.2	15.5
Research and development	142.2	107.7	427.5	345.8
Acquired in-process research and development	0.0	0.0	143.9	0.0
Selling, general and administrative	204.2	186.3	668.7	569.8
Total operating expenses	357.6	300.1	1,271.3	931.1
Operating income	141.2	87.8	100.6	145.6
Other income (expense):
Interest expense	(1.1)	(1.2)	(3.5)	(6.0)
Unrealized (loss) gain on equity security investments	(40.1)	11.1	(0.6)	23.6
Loss on extinguishment of convertible senior notes	0.0	0.0	0.0	(70.0)
Investment income and other, net	15.6	0.2	37.4	2.8
Total other (expense) income, net	(25.6)	10.1	33.3	(49.6)
Income before provision for income taxes	115.6	97.9	133.9	96.0
Provision for income taxes	32.5	29.4	31.9	30.5
Net income	83.1	68.5	102.0	65.5
Foreign currency translation adjustments, net of tax	(1.4)	0.0	0.7	0.0
Unrealized gain (loss) on debt securities available-for-sale, net of tax	0.8	(1.8)	5.5	(12.3)
Comprehensive income	$ 82.5	$ 66.7	$ 108.2	$ 53.2
Earnings per share:
Basic (in USD per share)	$ 0.85	$ 0.72	$ 1.05	$ 0.69
Diluted (in USD per share)	$ 0.82	$ 0.69	$ 1.01	$ 0.67
Weighted-average shares outstanding:
Basic (in shares)	97.9	95.8	97.5	95.6
Diluted (in shares)	101.1	99.0	100.6	98.3
Net product sales
Revenues:
Revenues	$ 491.8	$ 379.3	$ 1,353.4	$ 1,036.3
Collaboration revenues
Revenues:
Revenues	$ 7.0	$ 8.6	$ 18.5	$ 40.4

NBIX Balance Sheet

2023-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 293.7	$ 262.9
Debt securities available-for-sale	801.4	726.4
Accounts receivable	417.8	350.0
Inventories	28.8	35.1
Other current assets	108.2	79.1
Total current assets	1,649.9	1,453.5
Deferred tax assets	383.2	305.9
Debt securities available-for-sale	454.7	299.4
Right-of-use assets	80.8	87.0
Equity security investments	132.8	102.1
Property and equipment, net	68.8	58.6
Intangible assets, net	34.9	37.2
Other assets	43.1	25.0
Total assets	2,848.2	2,368.7
Current liabilities:
Accounts payable and accrued liabilities	503.0	347.6
Convertible senior notes	169.9	169.4
Other current liabilities	18.7	20.7
Total current liabilities	691.6	537.7
Noncurrent operating lease liabilities	85.9	93.5
Other long-term liabilities	68.6	29.7
Total liabilities	846.1	660.9
Stockholders’ equity:
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding	0.0	0.0
Common stock, $0.001 par value; 220.0 million shares authorized; 98.2 million and 96.5 million shares issued and outstanding, respectively	0.1	0.1
Additional paid-in capital	2,308.5	2,122.4
Accumulated other comprehensive loss	(1.7)	(7.9)
Accumulated deficit	(304.8)	(406.8)
Total stockholders’ equity	2,002.1	1,707.8
Total liabilities and stockholders’ equity	$ 2,848.2	$ 2,368.7

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Ã‚â€“ Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

CEO	Dr. Kevin C. Gorman Ph.D.
WEBSITE	www.neurocrine.com
EMPLOYEES	1350

Neurocrine Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

As of Fri Dec 08 2023, market cap of Neurocrine Biosciences Inc is 11.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart. The fair value of Neurocrine Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neurocrine Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neurocrine Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, NBIX's PE ratio (Price to Earnings) is 60.3 and Price to Sales (PS) ratio is 6.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Neurocrine Biosciences Inc's stock?

In the past 10 years, Neurocrine Biosciences Inc has provided 0.285 (multiply by 100 for percentage) rate of return.

Market Summary

NBIX Alerts

NBIX Stock Price

NBIX RSI Chart

NBIX Alerts

NBIX Valuation

NBIX Price/Sales (Trailing)

NBIX Profitability

NBIX Fundamentals

NBIX Revenue

NBIX Earnings

Price Action

How does NBIX drawdown profile look like?

NBIX Financial Health

NBIX Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for NBIX

Which funds bought or sold NBIX recently?

Latest Funds Activity

Schedule 13G FIlings of Neurocrine Biosciences Inc

Recent SEC filings of Neurocrine Biosciences Inc

NBIX Fair Value

Peers (Alternatives to Neurocrine Biosciences Inc)

Neurocrine Biosciences Inc News

Financials for Neurocrine Biosciences Inc

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

NBIX Income Statement

NBIX Balance Sheet

About Neurocrine Biosciences Inc

Neurocrine Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

What is the fair value of NBIX stock?

Is Neurocrine Biosciences Inc a good stock to buy?

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

What is 5 year return on Neurocrine Biosciences Inc's stock?

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)